Premium
Successful treatment of relapsing autoimmune thrombotic thrombocytopenic purpura with rituximab
Author(s) -
Sankararaman Senthilkumar,
Jeroudi Majed,
Ibrahim Hassan
Publication year - 2014
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12344
Subject(s) - medicine , rituximab , thrombotic thrombocytopenic purpura , thrombotic microangiopathy , plasmapheresis , refractory (planetary science) , immunology , dermatology , antibody , platelet , disease , physics , astrobiology
Thrombotic thrombocytopenic purpura ( TTP ) is a rare but life‐threatening condition characterized by thrombotic microangiopathy. The standard treatment for TTP is plasmapheresis. For refractory or relapsing cases, various immunosuppressive agents have been tried, and among them rituximab has shown promising results. TTP is rarer in the pediatric age group and the use of rituximab in children with TTP is limited. Reported herein is the successful treatment of relapsing autoimmune TTP with rituximab in a 12‐year‐old girl.